Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management

 

 Buy Article Permissions and Reprints

Abstract

There are multiple guidelines for managing patients with high-risk cardiovascular disease, and unfortunately for the practicing clinician, these guidelines are quite variable. Some are fairly specific whereas others are not, resulting in a great deal of confusion regarding whether management of low-density lipoprotein cholesterol (LDL-C) should be tailored only, targeted only, or managed by a combination of both. In the management of cardiovascular disease, favorable cardiovascular outcomes can be obtained by simply lowering the LDL-C in the absence of any other medications. The advent of statins, the most potent LDL-C–lowering medication yet when developed, provided benefits augmented by the presence of multiple pleiotropic effects. Tailoring and/or targeting the decrease in LDL-C is also an issue of concern. Then, in 2016, the new proprotein convertase sutilisin-like/kexin type 9 (PCSK9) inhibitors appeared, providing a solution to patients with high-risk cardiovascular disease with statin intolerance and those who did not attain a desired LDL-C level while on a high-dose statin. These new PCSK9 inhibitors necessitate a determination of how low the LDL-C can and should go, most likely safely down to a beneficial level of 25 mg/dL for the highest-risk patient. These issues are documented and discussed with an attempt to help the reader make an informed risk management decision.

• References

• 1 Bennet CS, Dahagam CR, Virani SS , et al. Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: a critique. Am J Med 2016; 129 (9) 906-912
  CrossrefPubMedGoogle Scholar
• 2 Stone NJ, Robinson JG, Lichtenstein A. The new cholesterol treatment guidelines. N Engl J Med 2014; 370 (20) 1957
  CrossrefPubMedGoogle Scholar
• 3 Stone NJ, Robinson JG, Lichtenstein AH , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Pt B): 2889-2934
  CrossrefPubMedGoogle Scholar
• 4 Stone NJ, Robinson JG, Lichtenstein AH , et al; 2013 ACC/AHA Cholesterol Guideline Panel. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014; 160 (5) 339-343
  PubMedGoogle Scholar
• 5 Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol 2014; 8 (1) 29-60
  CrossrefPubMedGoogle Scholar
• 6 Handelsman Y, Bloomgarden ZT, Grunberger G , et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract 2015; 21 (Suppl. 01) 1-87
  PubMedGoogle Scholar
• 7 Jacobson TA, Ito MK, Maki KC , et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol 2014; 8 (5) 473-488
  CrossrefPubMedGoogle Scholar
• 8 Reiner Z, Catapano AL, De Backer G , et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32 (14) 1769-1818
  CrossrefPubMedGoogle Scholar
• 9 Virani SS, Pokharel Y, Steinberg L , et al. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol 2016; 10 (3) 497-504.e4
  CrossrefPubMedGoogle Scholar
• 10 Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012; 5 (1) 2-5
  CrossrefPubMedGoogle Scholar
• 11 Hofer TP, Sussman JB, Hayward RA. New studies do not challenge the American College of Cardiology/American Heart Association Lipid Guidelines. Ann Intern Med 2016; 164 (10) 683-684
  CrossrefPubMedGoogle Scholar
• 12 Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987; 8 (4) 356-387
  CrossrefPubMedGoogle Scholar
• 13 Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257 (23) 3233-3240
  CrossrefPubMedGoogle Scholar
• 14 Buchwald H, Stoller DK, Campos CT, Matts JP, Varco RL. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg 1990; 212 (3) 318-329 , discussion 329–331
  CrossrefPubMedGoogle Scholar
• 15 Buchwald H, Varco RL, Boen JR , et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158 (11) 1253-1261
  CrossrefPubMedGoogle Scholar
• 16 Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004; 6 (1) 27-35
  CrossrefPubMedGoogle Scholar
• 17 Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PA. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med 2016; 164 (9) 600-607
  CrossrefPubMedGoogle Scholar
• 18 Schonfeld G. The hypobetalipoproteinemias. Annu Rev Nutr 1995; 15: 23-34
  CrossrefPubMedGoogle Scholar
• 19 Grundy SM, Cleeman JI, Merz CN , et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2) 227-239
  CrossrefPubMedGoogle Scholar
• 20 Whayne Jr TF. Assessment of low-density lipoprotein targets. Angiology 2013; 64 (6) 411-416
  CrossrefPubMedGoogle Scholar
• 21 Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232 (4746): 34-47
  CrossrefPubMedGoogle Scholar
• 22 Shahady E. Low-density lipoprotein cholesterol: how low should you go? And what about safety?. Consultant 2016; 56: S2-S4
  PubMedGoogle Scholar
• 23 Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E ; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46 (8) 1411-1416
  CrossrefPubMedGoogle Scholar
• 24 Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57 (16) 1666-1675
  CrossrefPubMedGoogle Scholar
• 25 Shepherd J, Cobbe SM, Ford I , et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20) 1301-1307
  CrossrefPubMedGoogle Scholar
• 26 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-1389
  PubMedGoogle Scholar
• 27 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19) 1349-1357
  CrossrefPubMedGoogle Scholar
• 28 Athyros VG, Papageorgiou AA, Mercouris BR , et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4) 220-228
  CrossrefPubMedGoogle Scholar
• 29 Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336 (3) 153-162
  CrossrefPubMedGoogle Scholar
• 30 Downs JR, Clearfield M, Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20) 1615-1622
  CrossrefPubMedGoogle Scholar
• 31 Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (6) 403-414
  CrossrefPubMedGoogle Scholar
• 32 McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59 (25) 2344-2353
  CrossrefPubMedGoogle Scholar